News & CommentAlzheimer's Research

Allen Roses: From 'Street Fighter' to Corporate Insider

See allHide authors and affiliations

Science  15 May 1998:
Vol. 280, Issue 5366, pp. 1001-1004
DOI: 10.1126/science.280.5366.1001

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

On 17 June, the British-based pharmaceutical giant Glaxo Wellcome named controversial Duke University neurologist Allen Roses head of its worldwide genetics research efforts, making him a member of an elite group of ex-academics running big industrial genetics programs. Roses now oversees a $50 million genetics budget, part of Glaxo's $2 billion annual R&D effort. In recent interviews with Science, Roses discussed his goals for genetics research at Glaxo and his battles with skeptics about his Alzheimer's work--battles that are legendary in the field and that say a great deal about the drive and approach that Roses brings to his new job.